Parabilis Medicines, Inc. Common Stock - Asset Resilience Ratio
Parabilis Medicines, Inc. Common Stock (PBLS) has an Asset Resilience Ratio of 2.86% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PBLS total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Parabilis Medicines, Inc. Common Stock's Asset Resilience Ratio has changed over time. See financial flexibility index of Parabilis Medicines, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Parabilis Medicines, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Parabilis Medicines, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $33.64 Million | 2.86% |
| Total Liquid Assets | $33.64 Million | 2.86% |
Asset Resilience Insights
- Limited Liquidity: Parabilis Medicines, Inc. Common Stock maintains only 2.86% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Parabilis Medicines, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Parabilis Medicines, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
Annual Asset Resilience Ratio for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Parabilis Medicines, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $80.82 Million | -- |
| 2024-12-31 | 27.27% | $40.69 Million | $149.25 Million | -- |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more